Lee Krug, MD Memorial Sloan-Kettering Cancer Center
Chair, Meso Foundation Science Advisory Board and Member, Meso Foundation Board of Directors
Lee M. Krug, MD, is an Associate Attending Physician in the Division of Thoracic Oncology, Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York, New York where he completed a fellowship and chief fellowship in medical oncology. Dr. Krug is the Director of the Mesothelioma Program at Memorial Sloan-Kettering Cancer Center. Dr. Krug has investigated multimodality approaches for patients with early stage malignant pleural mesothelioma. He led a multicenter U.S. trial of induction chemotherapy before extrapleural pneumonectomy, and he has a current study testing the feasibility of chemotherapy followed by pleural radiation. Dr. Krug also has a strong interest in novel therapeutics for patients with more advanced disease. He conducted a phase I trial with a WT-1 peptide vaccine, and he was awarded a grant from the Department of Defense to conduct a randomized phase II trial with this vaccine. He is also the principal investigator of an international, phase III trial of a histone deacetylase inhibitor, vorinostat. Dr. Krug led the committee for the National Comprehensive Cancer Network (NCCN) that established treatment guidelines for mesothelioma. He is the chair of the Scientific Advisory Board at the Meso Foundation and also serves on the Board of Directors.